Transcarotid transcatheter aortic valve implantation with a novel balloon expandable Myval (R) THV under the local anesthesia

Since it was first acquainted to us in 2002, transcatheter aortic valve implantation (TAVI) was rapidly applied and earned worldwide approval. TAVI is the standard of care for patients with symptomatic severe aortic stenosis (AS), at intermediate to high-risk and in some low-risk patients in light of the recent data, principally if it can be performed transfemoral approach.[1] Although many studies have shown that transfemoral TAVI (TF-TAVI) is better than other alternative approaches in terms of morbidity and mortality, it has been shown that alternative routes, transapical, transsubclavian- axillary, or transcarotid routes, are used successfully in patients in whom transfemoral access is not possible.[2,3] We presented transcarotid TAVI (TC-TAVI) with a novel balloon-expandable- Myval transcatheter heart valve (THV) system in patients with a prohibitive abdominal aortic disease, which is the first in the literature.